Related Experiment Video
Updated: Aug 21, 2026

Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay
Published on: December 19, 2018
Modulation of androgen receptor transcriptional activity by anti-acne reagents
Shigeki Inui1, Toshifumi Nakao, Satoshi Itami
1Department of Dermatology, Course of Molecular Medicine, Graduate School of Medicine, Osaka University, Osaka, 2-2, C5, Yamada-oka, Suita-shi, Osaka 565-0871, Japan. inui@derma.med.osaka-u.ac.jp
Background:
To study the potential anti-androgenic activity of roxithromycin (RXM), we previously used human dermal fibroblasts transiently transfected with the expression vector of androgen receptor (AR) coactivator ARA55 as the in vitro model reflecting the end-organ hypersensitivity.
Objective:
To examine the potential anti-androgenic activity of anti-acne therapeutic agents, nadifloxacin (NDFX), RXM, all-trans retinoic acid (atRA), and glycolic acid (GA), we carried out the transient transfection assays using the CV-1 cells as a more sensitive assay system.
Results:
The result showed that 5 microg/ml of RXM suppress 10(-9)M R1881-induced AR transcriptional activity by 21.2%. 50 microg/ml of NDFX can suppress AR transcriptional activity to 29.8%. Furthermore, the assays with treatment of 1, 5, 10, or 50 microg/ml NDFX in the presence of 1 microg/ml RXM showed that 5, 10, or 50 microg/ml NDFX inhibits the AR transactivity by 32.7, 31.1 or 61.0%, respectively, indicating the synergistic effect of NDFX and RXM. Besides 10(-5)M atRA suppressed the R1881-induced luciferase activity by 50%, but GA did not alter AR transactivity.
Conclusions:
We demonstrated that anti-acne agents available in the clinical practice can exert anti-androgenic effects in the treatment of acne.
Insights
This study investigated the anti-androgenic effects of common anti-acne medications. Nadifloxacin (NDFX) and roxithromycin (RXM) showed significant suppression of androgen receptor activity, with a synergistic effect observed when used together.
Area of Science:
- Pharmacology
- Dermatology
- Molecular Biology
Background:
- Previous studies explored roxithromycin's (RXM) anti-androgenic activity using human dermal fibroblasts and the androgen receptor (AR) coactivator ARA55.
- This research aimed to further investigate RXM and other anti-acne agents for their potential anti-androgenic properties.
Purpose of the Study:
- To evaluate the anti-androgenic activity of nadifloxacin (NDFX), RXM, all-trans retinoic acid (atRA), and glycolic acid (GA).
- To utilize CV-1 cells in transient transfection assays as a sensitive system for detecting anti-androgenic effects.
Main Methods:
- CV-1 cells were transiently transfected for androgen receptor (AR) transcriptional activity assays.
- Cells were treated with varying concentrations of NDFX, RXM, atRA, and GA, with R1881 used as an inducer.
Main Results:
- Roxithromycin (RXM) at 5 microg/ml suppressed R1881-induced AR activity by 21.2%.
- Nadifloxacin (NDFX) at 50 microg/ml suppressed AR activity by 29.8%.
- A combination of NDFX and RXM demonstrated a synergistic effect, with NDFX (5-50 microg/ml) inhibiting AR transactivity by 32.7-61.0% in the presence of RXM.
- All-trans retinoic acid (atRA) at 10(-5)M suppressed AR activity by 50%, while glycolic acid (GA) showed no significant effect.
Conclusions:
- The study demonstrates that commonly used anti-acne agents possess anti-androgenic properties.
- These findings suggest a potential mechanism for the efficacy of these agents in treating acne through the modulation of androgenic pathways.
Related Concept Videos
Acne Infection
Internal Receptors
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
Co-activators and Co-repressors
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...

